Thar Pharmaceuticals

General Information
Business:

We are a clinical stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, oral therapies designed to solve clinical limitations of existing intravenous only therapies for serious and life threatening conditions. Using our proprietary Enhance technology platform, we developed our lead product candidate, T121, for the treatment of pain associated with complex regional pain syndrome, or CRPS, a debilitating, orphan condition. We plan to initiate the first of two, double blind, placebo-controlled, multisite Phase 3 clinical trials of T121 for the treatment of pain associated with CRPS in the first quarter of 2017. Using our Enhance technology, we plan to create a pipeline of novel, patentable oral drug therapies by modifying the relevant physicochemical properties of IV-only drugs, which we believe can improve the pharmacokinetics and clinical performance of the original drug.

Industry: PHARMACEUTICAL PREPARATIONS
Employees: 6
Founded: 2006
Contact Information
Address 150 Gamma Drive Pittsburgh, Pennsylvania 15238, USA
Phone Number (412) 963-6800
Web Address http://www.tharpharma.com
View Prospectus: Thar Pharmaceuticals
Financial Information
Market Cap
Revenues $0.2 mil (last 12 months)
Net Income $-4.47 mil (last 12 months)
IPO Profile
Symbol THAR
Exchange NASDAQ
Shares (millions): 0.0
Price range $0.00 - $0.00
Est. $ Volume $50.0 mil
Manager / Joint Managers SunTrust Robinson Humphrey
CO-Managers -
Expected To Trade:
Status: Withdrawn
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change